<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176278</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2013.609-T</org_study_id>
    <nct_id>NCT02176278</nct_id>
  </id_info>
  <brief_title>Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT)</brief_title>
  <acronym>DKD-TMT</acronym>
  <official_title>Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT) (DKD-TMT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asia Diabetes Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asia Diabetes Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this quality improvement program (DKD-TMT), patients will be recruited from multiple sites
      across Asia, with each site recruiting at least 300 type 2 diabetic patients with Diabetic
      Kidney Disease (DKD). After explanation by trained doctors and nurses, and with written
      informed consent, patients will be randomized to the UC (n=100, usual care) group, the EC
      (n=100, empowered care) group, or the TEC (n=100, team-based, empowered care) group. Patients
      in all 3 groups will undergo a comprehensive assessment (CA) guided by the templates in the
      Joint Asia Diabetes Evaluation (JADE) portal at baseline and at month 12. They will also
      self-administer a set of questionnaires for assessing quality of life and psychological
      distress during the CA at both time points.

      During the 12 months between the 2 CAs:

        -  Patients in the UC group will receive UC in accordance to the practice of the health
           institution.

        -  Patients in the EC group will receive a JADE summary report with personalized risk
           prediction, treatment targets and decision support with explanation from the doctor and
           nurse. In addition to receiving UC in accordance to the practice of the health
           institution, the nurse will telephone the patient 3-monthly to remind them to adhere to
           treatment, provide support and empower them to discuss with their doctors about their
           treatment needs and any concerns.

        -  Patients in the TEC group will be followed by a doctor-nurse team at least 3 monthly to
           achieve multiple targets, but tailored to patients' risk profile. The patients will
           receive telephone reminders and also be given a JADE follow up report 3-monthly.

      The primary composite endpoint is attainment of treatment goals and/or control of risk
      factors. The secondary composite endpoint is all-diabetes related clinical endpoints. The
      tertiary changes are behavioral changes, psychological well-being and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Patient empowerment and team-based care augmented by the JADE program with
      features of risk stratification and decision support improves multiple risk factor control in
      Asian type 2 diabetic patients with chronic kidney disease. Attaining multiple treatment
      targets reduces all diabetes-related endpoints in these high risk patients.

      Objectives: To use the JADE program which 1) includes task delegation and change in workflow
      augmented by 2) a web-based portal consisting of features of risk stratification, feedback,
      recommendations and decision support to set up a DKD registry in order to 1) document control
      of risk factors and care standards in real practice in Asian type 2 diabetic patients; 2)
      empower doctors and patients to make informed decisions and 3) use a team approach to treat
      to multiple targets and reduce all diabetes related clinical outcomes.

      Study design: This will be a multicentre randomized translational program to compare the
      effects of usual care (UC) versus empowered care (EC) versus team-based, empowered care (TEC)
      on risk factor control and clinical outcomes in 3000 patients with DKD in Asian countries.

      Intervention: All patients will undergo a comprehensive assessment (CA) guided by the
      templates in the JADE portal at baseline and at month 12. All patients will also
      self-administer a set of questionnaires for assessing quality of life (EQ-5D-3L, WHOQOL-BREF,
      and a Time Trade-Off (TTO) question) and psychological distress (PHQ-9 and DASS-21) during
      the CA at baseline and at month 12.

      During the 12 months between the 2 CAs:

        -  Patients in the UC group will receive UC in accordance to the practice of the health
           institution.

        -  Patients in the EC group will receive a JADE summary report with personalized risk
           prediction, treatment targets and decision support with explanation from the doctor and
           nurse. In addition to receiving UC in accordance to the practice of the health
           institution, the nurse will telephone the patient 3-monthly to remind them to adhere to
           treatment, provide support and empower them to discuss with their doctors about their
           treatment needs and any concerns.

        -  Patients in the TEC group will be followed by a doctor-nurse team at least 3 monthly to
           achieve multiple targets, but tailored to patients' risk profile. The patients will
           receive telephone reminders and also be given a JADE follow up report 3-monthly.

      Outcome: The primary composite endpoint is attainment of treatment goals and/or control of
      risk factors. The secondary composite endpoint is all-diabetes related clinical endpoints.
      The tertiary changes are behavioral changes, psychological well-being and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attainment of at least 3 treatment targets</measure>
    <time_frame>1 year</time_frame>
    <description>Attainment of at least 3 treatment targets of
A1c&lt;7%
BP&lt;130/80 mmHg
LDL-C&lt;1.8 mmol/L
Triglyceride&lt;1.7 mmol/L
Persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-diabetes related endpoints</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of all-diabetes related endpoints (vascular, cancer, non-vascular non-cancer and all-cause death) between patients who attain at least 3 targets versus those who do not</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in A1c</measure>
    <time_frame>1 Year</time_frame>
    <description>To examine the absolute and % changes in A1c amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in eGFR</measure>
    <time_frame>1 Year</time_frame>
    <description>To examine the absolute and % changes in eGFR amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Use of medication</measure>
    <time_frame>1 year</time_frame>
    <description>To understand the use of medications including statins, RAS inhibitors and insulin amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of ESRD and all-cause death</measure>
    <time_frame>1 year</time_frame>
    <description>To examine the difference of incidence of ESRD and all-cause death between patients who are treated to multiple targets and those who are not</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of all CV events</measure>
    <time_frame>1 year</time_frame>
    <description>To investiage the difference of incidence of all CV events including stroke, acute myocardial infarction, heart failure, acute coronary syndrome, all-cause death between patients who are treated to multiple targets and those who are not</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of all-site cancer and all-cause death</measure>
    <time_frame>1 year</time_frame>
    <description>To examine incidence of all-site cancer and all-cause death between patients who are treated to multiple targets and those who are not</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness and quality of life analysis</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in lipid</measure>
    <time_frame>1 year</time_frame>
    <description>To examine the absolute and % changes in lipids amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in BP</measure>
    <time_frame>1 year</time_frame>
    <description>To examine the absolute and % changes in BP amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>1 year</time_frame>
    <description>To exmine the absolute and % changes in body weight amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in albuminuria</measure>
    <time_frame>1 year</time_frame>
    <description>To exmine the absolute and % changes albuminuria amongst the UC, EC and TEC groups</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care (UC) group:
After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empowered Care Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empowered care (EC) group:
After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Team-based, Empowered Care Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Team-based, empowered care (TEC) group:
After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone Reminder</intervention_name>
    <description>Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns</description>
    <arm_group_label>Empowered Care Group</arm_group_label>
    <arm_group_label>Team-based, Empowered Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Doctor-Nurse Follow Up</intervention_name>
    <description>Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c&lt;7%, BP&lt;130/80 mmHg, LDL-C&lt;1.8 mmol/l, triglyceride&lt;1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.</description>
    <arm_group_label>Team-based, Empowered Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Personalized Risk Report for Patient Empowerment</intervention_name>
    <description>Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.</description>
    <arm_group_label>Empowered Care Group</arm_group_label>
    <arm_group_label>Team-based, Empowered Care Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients with serum creatinine above 30% upper limit of normal of the
             laboratory range and/or estimated glomerular filtration rate (eGFR)&lt; 65ml/min/1.73m2;
             or type 2 diabetic patients with both eGFR between 60 to 90ml/min/1.73m2 and urine
             albumin creatinine ratio (ACR) â‰¥ 25 mg/mmol.

          -  Willingness to return for regular follow up visits

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Life threatening condition with reduced life expectancy

          -  Patients on dialysis or eGFR&lt;15 ml/min/1.732
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana CN Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asia Diabetes Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliana CN Chan, MD</last_name>
    <phone>+852 26461397</phone>
    <email>jchan@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy WC FU, MPH</last_name>
    <phone>+852 26461397</phone>
    <email>afu@adf.org.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Forth Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shengyang City</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Du</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese University of Hong Kong, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana CN Chan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital, The Catholic Unviersity of Korea</name>
      <address>
        <city>Seocho-Gu</city>
        <state>Seoul</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun-Ho Yoon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Gyenonggo-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soon-Jub Yoo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hally University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggido</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Gyong Hong, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universiti Sains Malysia</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mafauzy Mohamed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre, University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tan Alexander</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre, University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yook Chin Chia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chii-Min Hwu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Theptarin Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yotsapon Thewjitcharoen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoa Hao MEDIC Company LMT</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thy Khue Nguyen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://adf.org.hk</url>
    <description>Asia Diabetes Foundation</description>
  </link>
  <link>
    <url>http://www.idfce-hk.org/</url>
    <description>The Chinese University of Hong Kong - Prince of Wales Hospital International Diabetes Federation (IDF) Centre of Education</description>
  </link>
  <reference>
    <citation>Chan J, So W, Ko G, Tong P, Yang X, Ma R, Kong A, Wong R, Le Coguiec F, Tamesis B, Wolthers T, Lyubomirsky G, Chow P. The Joint Asia Diabetes Evaluation (JADE) Program: a web-based program to translate evidence to clinical practice in Type 2 diabetes. Diabet Med. 2009 Jul;26(7):693-9. doi: 10.1111/j.1464-5491.2009.02751.x.</citation>
    <PMID>19573118</PMID>
  </reference>
  <reference>
    <citation>Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, Lau KP, Siu SC, Li JK, Yeung VT, Leung WY, Tong PC; SURE Study Group. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care. 2009 Jun;32(6):977-82. doi: 10.2337/dc08-1908.</citation>
    <PMID>19460913</PMID>
  </reference>
  <reference>
    <citation>Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, Chan JC. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ. 2006 Sep 9;333(7567):522. Epub 2006 Aug 17.</citation>
    <PMID>16916809</PMID>
  </reference>
  <reference>
    <citation>Leung WY, So WY, Tong PC, Chan NN, Chan JC. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005 Dec;118(12):1414.</citation>
    <PMID>16378791</PMID>
  </reference>
  <reference>
    <citation>Leung WY, So WY, Tong PC, Lo MK, Lee KF, Ko GT, Chan WB, Cockram CS, Brenner BM, Shahinfar S, Critchley JA, Chan JC. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant. 2004 Oct;19(10):2519-25. Epub 2004 Jul 27.</citation>
    <PMID>15280527</PMID>
  </reference>
  <reference>
    <citation>Chan JC, Sui Y, Oldenburg B, Zhang Y, Chung HH, Goggins W, Au S, Brown N, Ozaki R, Wong RY, Ko GT, Fisher E; JADE and PEARL Project Team. Effects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: a randomized clinical trial. JAMA Intern Med. 2014 Jun;174(6):972-81. doi: 10.1001/jamainternmed.2014.655.</citation>
    <PMID>24781960</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Kidney Disease</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Asian</keyword>
  <keyword>Joint Asia Diabetes Evaluation (JADE) Program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

